127 related articles for article (PubMed ID: 20660828)
21. Optimising the design of phase II oncology trials: the importance of randomisation.
Ratain MJ; Sargent DJ
Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
[TBL] [Abstract][Full Text] [Related]
22. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
23. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
[TBL] [Abstract][Full Text] [Related]
24. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
25. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
26. Another STEPP in the right direction.
Bonetti M; Cole BF; Gelber RD
J Clin Oncol; 2008 Aug; 26(22):3813-4; author reply 3814-5. PubMed ID: 18669475
[No Abstract] [Full Text] [Related]
27. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
Sweetenham JW
Bone Marrow Transplant; 2001 Nov; 28(9):813-20. PubMed ID: 11781640
[TBL] [Abstract][Full Text] [Related]
28. NCI launches an innovative design for a breast cancer clinical trial.
Whitworth A
J Natl Cancer Inst; 2006 Sep; 98(17):1178-9. PubMed ID: 16954467
[No Abstract] [Full Text] [Related]
29. [Methodological aspects of biostatistics and epidemiology in a clinical trial].
Suárez E; Pérez CM
P R Health Sci J; 1999 Mar; 18(1):23-30. PubMed ID: 10343983
[TBL] [Abstract][Full Text] [Related]
30. Up-front versus sequential randomizations for inference on adaptive treatment strategies.
Ko JH; Wahed AS
Stat Med; 2012 Apr; 31(9):812-30. PubMed ID: 22362642
[TBL] [Abstract][Full Text] [Related]
31. Other paradigms: randomized discontinuation trial design.
Stadler W
Cancer J; 2009; 15(5):431-4. PubMed ID: 19826364
[TBL] [Abstract][Full Text] [Related]
32. Autologous hematopoietic stem cell transplantation for pediatric solid tumors.
Hale GA
Expert Rev Anticancer Ther; 2005 Oct; 5(5):835-46. PubMed ID: 16221053
[TBL] [Abstract][Full Text] [Related]
33. Prediction and causal inference.
Gagliardi L
Acta Paediatr; 2009 Dec; 98(12):1890-2. PubMed ID: 20050836
[No Abstract] [Full Text] [Related]
34. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
35. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
[TBL] [Abstract][Full Text] [Related]
36. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial.
Ribera JM; Ortega JJ; Oriol A; Bastida P; Calvo C; Pérez-Hurtado JM; González-Valentín ME; Martín-Reina V; Molinés A; Ortega-Rivas F; Moreno MJ; Rivas C; Egurbide I; Heras I; Poderós C; Martínez-Revuelta E; Guinea JM; del Potro E; Deben G
J Clin Oncol; 2007 Jan; 25(1):16-24. PubMed ID: 17194902
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant chemotherapy in invasive bladder cancer. Trial design.
Parmer MK
Prog Clin Biol Res; 1990; 353():115-8. PubMed ID: 2217408
[No Abstract] [Full Text] [Related]
38. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
Sharma MR; Maitland ML; Ratain MJ
Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
[TBL] [Abstract][Full Text] [Related]
39. Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived.
Waselenko JK; Flynn JM; Byrd JC
Semin Oncol; 1999 Feb; 26(1):48-61. PubMed ID: 10073561
[TBL] [Abstract][Full Text] [Related]
40. Methods for mid-course corrections in clinical trials with survival outcomes.
Cook TD
Stat Med; 2003 Nov; 22(22):3431-47. PubMed ID: 14601011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
